DOCSLIB.ORG

Mdphd Alumni

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

I MD/PhD Graduates Year MD/PhD Graduate Advisor PhD Subject Residency Position 1 1988 Brian Czerniecki '82 Gisela Witz Toxicology 1987 Resident, Surgery, Ohio State U. Professor and Chair of Breast Oncology at * Hospitals, OH Moffitt Cancer Center, Tampa FL 2 1989 Kelly McMasters '88 Gordon Mac Donald Cell & Developmental Biology Resident, Surgery, U. Louisville School of Endowed Professorship: Ben A. Reid, Sr., 1988 Med., KY MD Professor and Chair Surgery, Div. of Surgical Oncology, Univ. of Louisville, KY 3 1990 Thomas Giordano '88 William McAllister Microbiology 1988 Resident, Pathology, National Institutes Henry Clay Bryant Professor of Pathology, * of Health, MD Director, Division of Molecular & Genomic Pathology, Univ. of Michigan Medical School, Ann Arbor, MI 4 1990 Arthur Vasen '89 Michael Lewis Psychology 1987 Resident, Orthpaedics, U. Hospital of Hand & Upper Extremity Orthopaedic Cleveland, OH Surgeon, Seaview Orthopaedic & Medical Associates, Ocean.NJ 5 1992 Jeanine D'Armiento '87 Kiran Chada Biochemistry & Molecular Resident, Internal Medicine, Presbyterian Associate Professor of Medicine in Biology 1990 Hospital, NY Anesthesiology, Director, Center for Molecular Pulmonary Disease in Anesthesiology & Physiology, and Cellular Biophysics, Director, Center for LAM and Rare Lung Disease, Columbia Univ., Dept. of Medicine, NY 6 1993 Sharon Pan '88 Kiran Chada Biochemistry & Molecular Resident, Pediatrics, Mt. Sinai Hospital, Attending Physician, Pediatric Emergency Biology 1991 NY Dept., New York-Presbyterian Hospital, NY 7 1994 Richard Leone '91 Gary Merill Physiology & Neurobiology Resident, Categorial General Surgery, Associate Medical Director of 1992 UMDNJ-Robert Wood Johnson, NJ Cardiothoracic Surgery, St Joseph Cardiothoracic Surgery Associates, WA 8 1997 Michael Farrell '91 Celines Gelinas Biochemistry & Molecular Resident, Internal Medicine, Univ. of Attending Physician, Biology 1995 Rochester Strong Memorial, NY Hematology/Oncology, Connecticul Oncology Group Middlesex Hospital, Middletown, CT 9 1997 Shawn Field '90 Gary Drzewiecki Biomedical Engineering 1995 Resident, Family Medicine, John F. Kennedy Hospital, NJ Private Practice, NJ 10 1997 Godwin Okoye '89 Herbert Geller Pharmacology - 1994 Resident, Internal Medicine Preliminary, Diversity Opthalmology, Howard University, DC N/A 11 1998 Ronny Drapkin '90 Danny Reinberg Biochemistry & Molecular Resident, Pathology, Brigham & Director, Gynecologic Cancer Research, * Diversity Biology - 1996 Women's Hospital, MA Basser Center for BRCA, Director Ovarian Cancer Center, Franklin Payne Associate Professor of Pathology in Obstetrics & Gynecology, University of Pennsylvania, 12 1998 Miriam Lefkowitz-Weisbrot Masayori Inouye Biochemistry & Molecular Resident, Internal Medicine, Robert ''94 Biology 1998 Wood Johnson University Hospital, NJ Private Practice, NJ Year MD/PhD Graduate Advisor PhD Subject Residency Position 13 1998 Genevieve Neal-Perry '91 William Nicklas Pharmacology - 1996 Resident, OB/GYN, Beth Israel Medical Diversity Center, NY - Associate Professor, Division Director, Assistant Professor of Obstetrics and Reproductive Endocrinology and Infertility, Gynecology, Albert Einstein College of Department of Obstetrics & Gynecology, Medicine, NY University of Washington 14 1998 Evan Wolf 91 Emanuel DiCicco- Physiology & Neurobiology Resident, Internal Medicine, Preliminary, * Bloom 1996 Ophthalmology, University of Utah Affil. President, Valley Eye Associates, Wasilla, Hospital HSC-UT AK 15 1999 Nicholas DiProspero '94 Herbert Geller Pharmacology 1997 Resident, Internal Medicine, Senior Director, Translational Medicine, Georgetown, DC The Janssen Pharmaceutical Companies of Johnson & Johnsonk, NJ 16 1999 Kevin Ryan ''96 Steven Anderson Chemistry Resident, Neurology, University of Miami, Jackson Hospital, FL N/A 17 2000 Paul Haluska '95 Eric Rubin Pharmacology 1998 Resident, Internal Medicine, Clinical * Investigator Track, Mayo Graduate Global Director of Scientific Affairs, School of Medicine, AZ Oncology, Merck, NJ 18 2000 Emilio Mazza '92 Judith Neubauer Physiology & Neurobiology Resident, Internal Medicine, Clinical * 1999 Investigator Track, Hospital of the Staff Pulmonologist/Intensivist at Virtua- University of Penn., PA Garden State Pulmonary Associates, NJ 19 2000 Gina Northington '93 Stanley Dunn Biomedical Engineering - Resident, OB/GYN, Wayne State Associate Professor, Division Director and Diversity 2000 University, Detroit Medical Center, MI Fellowship Director, Female Pelvic Medicine and Surgery, Chief of Service for Gynecology, Emory University, GA 20 2000 Brian Pollack '91 Sidney Pestka Molecular Genetics & Resident, Internal Medicine Preliminary, Microbiology 1998 Mary Imogene Bassett, Cooperstown, Assistant Professor, Department of NY Dermatology, Emory University, Dermatology and Pathology/Laboratory School of Medicine, GA Medicine, Emory University, School of Medicine, GA 21 2001 James Creeden '96 Susan Quinones Toxicology 1999 Transitional year, St. Barnabas, NJ - * Radiology, Columbia Presbyterian, NYC Medical Director, Asia-Pacific Region at Roche, China 22 2001 Troy Edwards '94 Eric Rubin Pharmacology - 2000 Resident, Surgery Preliminary, Urology, * Diversity Robert Wood Johnson University Urology Physician, Orlando Health Hospital, NJ Physician Group, Inc., FL 23 2001 Jennifer Hamilton '94 Evangelia Micheli- Biomedical Engineering 2000 Resident, Family Medicine, Robert Wood Associate Professor, Family, Community & * Tzanakou Johnson University Hospital, NJ Preventive Medicine, Drexel Family Medicine, Center foer Women's Health, PA 24 2001 Howard Levene '94 Joachim Kohn Biomedical Engineering 1999 Resident, Surgery Preliminary, Surgeon, Assistant Professor of Clinical Neurosurgery, Temple University Neurological Surgery,University of Miami Hospital, PA Health System, FL 25 2001 Hany Michail '94 Stanley Dunn Biomedical Engineering 2000 Transitional year, St. Barnabas, NJ - Opthalmology, Washington University, St. Louis Attending Physician, Modesto CA Year MD/PhD Graduate Advisor PhD Subject Residency Position 26 2002 Neal Moskowitz '93 Joseph Germino Molecular Genetics & Resident, Internal Medicine, Robert Attending Rheumatologist and Partner at Microbiology 2000 Wood Johnson University Hospital, NJ Arthritis Group, Phila, PA 27 2002 Tanya Zaremba (Fisher) Cheryl Dreyfus Physiology & Neurobiology Resident, Internal Medicine Preliminary, * '94 2000 Greenwich Hospital, CT; Neurology, Yale University Hospital, New Haven, CT Attending Neurologist, Private Practice, West Haven, CT 28 2003 Janivette Alsina '96 Masayori Inouye Biochemistry & Molecular Resident, Surgery, University of Chicago * Diversity Biology - 2001 Hospital, ILL Surgeon, Oncology, Hepatobiliary Surgery, D'Amour Center for Cancer Care, MS 29 2003 Irina Burd '00 William Moyle Molecular Genetics & Resident, OB/GYN, Thomas Jefferson Director, Integrated Research Center for Microbiology 2003 University, PA Fetal Medicine, Associate professor of OB/GYN, Johnss Hopkins, MD 30 2003 John Schiltz '94 Kiran Chada Biochemistry & Molecular Resident, Psychiatry, Robert Wood Psychiatrist, Community Howard Regional * Biology 2001 Johnson Medical School, NJ Hospital, IN 31 2004 Soumit Basu '95 Masayori Inouye Biochemistry & Molecular Resident, Internal Medicine, Cleveland Assistant Professor of Medicine, Osborn Biology 2002 Clinic Fdn., OH Program in Hematologic Malignancies and Blood/Marrow Transplantation and Medical Director, West Virginia University School of Medicine, WV 32 2004 Joshua Nitsche '96 John Pintar Neuroscience 2002 Resident, OB/GYN, Mayo School of Assistant Professor, Maternal-Fetal Medicine, Rochester, MN Medicine,Obstetrics, Wake Forest Baptist Medical Center, NC 33 2004 Zeeshaan Rasheed '97 Eric Rubin Cellular & Molecular Resident, Internal Medicine, Research Medical Affairs Leader, Global Medical Pharmacology 2002 Track, Mt. Sinai, NY Affairs, Immuno-Oncology , AstraZeneca, MD 34 2004 Elizabeth Robinson '01 Ramsey Foty/Siohban Molecular Genetics, Resident, Surgery, UCLA, CA Corbett Microbiology & Immunology General Surgery Catagorical Resident, UCLA 2003 Medical Center 35 2004 Hilary Vernon '01 Jay Tischfield Molecular Genetics, Postdoctoral Fellow, Rutgers University, Assistant Professor, Medical Genetics, Microbiology & Immunology NJ, 7/05 Resident, Pediatric Genetics, Johns Hopkins University. Chair, Maryland 2004 Johns Hopkins University Hospital, MD State Advisory Council on Hereditary and Congenital Disorder, MD 36 2005 Paul F. Lizzul '96 Celines Gelinas Molelcular Genetics, Resident, Internal Med, Preliminary Chief Medical Officer, Sienna * Microbiology & Immunology Greenwich Hospital, Yale CT, Biopharmaceuticals, California Health & 2002 Dermatology, Univ of CA, Davis School Longevity Institute Inc., CA of Medicine 37 2005 Arvin Yang '97 Edmund Lattime Molecular Genetics, Resident, Internal Medicine, Beth Israel Group Director, Immuno-Oncolgy Clinical Microbiology & Immunology Deaconess, Boston MA Lead, Life Cycle Management, Bristol- 2003 Myers Squibb, NJ 38 2006 Parima Daroui '01 Leroy Liu Cellular & Molecular Transitional year, Radiation Oncology, St Assistant Professor, Radiation Oncology, Pharmacology 2004 Barnabas Med Ctr, Resident, Radiation University of Califorania - Irvine Oncology , RWJUH, NB Year MD/PhD Graduate Advisor PhD Subject Residency Position 39 2006 Bijal Parikh '98 Nilgum Tumer Microbiolgy & Molecular Postdoctoral Fellow, Pathology, Cancer Instr. In Pathology & Immunology, Genetics 2004 Institute of NJ (CINJ) 1-yr, Resident, Laboratory
Recommended publications
  • Robert Wood Johnson Medical School Retired Faculty Association Newsletter

    Robert Wood Johnson Medical School Retired Faculty Association Newsletter

    ROBERT WOOD JOHNSON MEDICAL SCHOOL RETIRED FACULTY ASSOCIATION NEWSLETTER JANUARY 2017 VOLUME X, NO. 1 UPCOMING RFA MEETING IN VITRO FERTILIZATION: AN EMBRYONIC HISTORY “A Robot’s View of Our Ocean Planet” By Eckhard Kemmann, MD When I started my training in Obstetrics- Gynecology at SUNY Downstate-Kings County Hospital in Brooklyn almost five decades ago, infertility was encountered by ten percent of couples, and treatment options were limited and primarily surgical. My teachers and mentors at the institution represented different aspects of the presently evolving field of reproductive medicine. Dr. A. Siegler was a pioneer in tubal surgery and laparoscopy – in the 80s he would introduce laparoscopy to China. Dr. J. R. Jones was an early expert in reproductive hormone research, and Dr. A. Gemzell had come from Sweden where he faced mandatory retirement at the age of 65 and brought his expertise to the United States in the use of ovulation induction. Dr. Gemzell was the first to isolate and use (continued on page 2) Josh Kohut, Ph.D. Associate Professor, Department of Marine TABLE OF CONTENTS PAGE and Coastal Science, Rutgers University Upcoming Meeting 1 InT Vitro Fertilization: An Embryonic History Friday, March 3, 2017 by Eckhard Kemmann, MD 1 Noon – 1:30 p.m. Dean’s Conference Room I See You by Elliot Sultanik, MD, Class of 2016 4 Rutgers Robert Wood Johnson Medical School RWJMS RFA Election Results 5 Piscataway, New Jersey Retired RWJMS Faculty Program to Mentor Medical Students 5 All current and retired faculty, staff, and students Faculty Transition to Retirement Program 6 are welcome to attend.
  • Sidney Pestka Sid Died Dec. 22, 2016, Surrounded by Family. The

    Sidney Pestka Sid Died Dec. 22, 2016, Surrounded by Family. The

    Sidney Pestka Sid died Dec. 22, 2016, surrounded by family. The quintessential scientist since adolescence, he had been afflicted with dementia for the last few years of his life. Born in Drobin, Poland, at 21 months of age he moved near family to the Williamsburg neighborhood of Brooklyn, and then at age 8 to Trenton, where he excelled at Trenton Central High School. He received a scholarship to Princeton University, from where he graduated summa cum laude with a B.A. in chemistry. He received his medical degree from the University of Pennsylvania School of Medicine on full scholarship. Afterwards, he worked at the National Institutes of Health in the laboratory of Marshall W. Nirenberg. Sid’s early work on the genetic code, protein synthesis and ribosome function led to Nirenberg’s 1968 Nobel Prize in Physiology or Medicine. In 1969, Sid left the NIH for the Roche Institute of Molecular Biology, where he focused on defining how antibiotics worked and proteins are synthesized and, later, interferons. There he was first to purify interferon alpha and beta; the first to clone mature interferons; and the first to develop a commercialized recombinant biotherapeutic—Roferon A. Sid is known as the "Father of Interferon" for his seminal work on interferon, work that gave birth to a $6 billion dollar market directed at the therapy of hepatitis, multiple sclerosis, cancer, and other diseases that affect mankind. Sid was Emeritus Professor of the Department of Biochemistry and Molecular Biology at Robert Wood Johnson Medical School of Rutgers, The State University of New Jersey, which he joined in 1986 and where he served as Chairman for 25 years.
  • NJ's Top 10 Scientists

    NJ's Top 10 Scientists

    NJ’s Top 10 Scientists here are more than 400,000 scientists and engineers in New Jersey hard at work each day delivering breakthrough medicines and technologies that save lives, improve our quality of life and keep our T economy competitive. With the cooperation of the leading technology trade associations in the state, New Jersey Business magazine is proud to present who we think are the “cream of the crop” in innovation: NJ’s Top 10 Scientists. Through their hard work and dedication, these men and women have made significant contributions to their companies, research institutions and society at large. Whether it is a biotechnology drug that helps fight cancer or AIDS, or a new kind of organic, light-emitting device that is four times more efficient than liquid crystal displays, these and other innovations from the scientists profiled are testaments to the research and development work being conducted in “The Innovative State”. We extend our appreciation to The Healthcare Institute of New Jersey, BioNJ, The New Jersey Research & Development Council, the New Jersey Technology Council and the Chemical Council of New Jersey for their assistance in gathering the nominations. The editors at New Jersey Business selected the final winners based on the impact their work has on society at large. A special recognition is being given to one scientist who, after the judging was completed, announced his retirement. Here, we present the innovators in alphabetical order: SPECIAL RECOGNITION Magid Abou-Gharbia, Ph.D., Senior Vice President and Head (Retired), Chemical and Screening Sciences, Wyeth Drug Discovery and Development, South Brunswick, NJ In October, Magid Abou-Gharbia, Ph.D., retired after 26 years with Wyeth Drug Discovery and Development – but not before leaving his mark in the pharmaceutical industry.
  • 2012-2013 Seminars

    2012-2013 Seminars

    2012-13 Archived Seminars 8/14/14 12:42 PM A Cornell University • Deparhnent of Iv1olecular Biology and Genetics 2012-13 Archived Seminars May 24, 2013 Speaker: Julius Lucks Department of Chemical and Biomedical Engineering Cornell University Title: "Towards Unraveling the RNA Sequence-Structure Code Using High Throughput RNA Structrure Characterizaion" Host: Sylvia Lee http://www.cheme.cornell.edu/people/profile.cfm?netid=jl564 May 17, 2013 W. Lee Kraus Distinguished Chair & Director, Cecil H. and Ida Green Ctr. for Reproductive Biology Sciences Professor & Vice Chair for Basic Science, Dept of Ob/Gyn Professor, Department of Pharmacology University of Texas Southwestern Medical Ctr. @ Dallas Title: "Chromatin-Mediated Gene Regulation by PARP-1: Control of Cellular Signaling and Differentiation Programs" Host: John Lis http://www.utsouthwestern.edu/education/medical-school/departments/green-center/index.html May 9, 2013 (THURSDAY) Brenton Graveley University of Connecticut Health Center Genetics and Developmental Biology Title: "Insights into RNA Biology in Drosophila from Genome-Wide Studies" Host: Jeff Pleiss http://genetics.uchc.edu/faculty/assoc_professors/graveley.html May 3, 2013 Bill Kelly Emory University Department of Biology Title: "Remembrance of Transcriptiones Past: Germline-Specific Modes of Transcription Regulation in C. elegans" Host: Kelly Liu http://www.biology.emory.edu/research/Kelly/members/Bill.html April 26, 2013 Kevin Struhl Harvard Medical School Dept. of Biological Chemistry & Molecular Pharmacology Title: "Transcriptional
  • A-Interferon Structure and Natural Killer Cell Stimulatory Activity1

    A-Interferon Structure and Natural Killer Cell Stimulatory Activity1

    [CANCER RESEARCH 50. 5328-5332, September 1, 1990] a-Interferon Structure and Natural Killer Cell Stimulatory Activity1 Bo-Liang Li,2 Xiao-Xia Zhao,3 Xin-Yuan Liu,2 Hyon Suk Kim, Karel Raska, Jr., John R. Ortaldo, Barbara Schwartz, and Sidney Pestka4 Departments of Molecular Genetics and Microbiology [B.-L. L., X-X. Z.. X-Y. L., B. S., S. P.] and Pathology [H. S. A., A'. R.J, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, Piscataway, Sew Jersey 08854, and National Cancer Institute, Frederick Cancer Research Facility, Frederick, Maryland 217011J. R.O.I ABSTRACT chased from New England BioLabs, T4 DNA ligase from International Biotechnologies Inc., polynucleotide kinase and deoxyribonucleotide Expression vectors for human a-interferon (Hu-IFN-a) .11. a site- triphosphates from P-L Biochemicals, and [«-"SjATP and [7-12P]ATP specific mutant |Ser"6]Hu-IFN-aJl, and Hu-IFN-aJ/C or Hu-IFN-aC/ from Amersham Corporation. J hybrids were constructed and expressed in Escherichìacoli. These Oligonucleotide-directed Site-specific Mutagenesis. M13mp8 Rf interferons and others were purified by immunoaffinity chromatography DN A was digested with £coRIand Hindi (Fig. 1) and then precipitated with a monoclonal antibody against human a-interferon. Their antiviral by equal volumes of 13% polyethylene glycol/1.6 M NaCl (9). The activity and ability to stimulate natural killer cell activity were determined precipitate was dissolved in 0.01 M Tris •HCl,pH 7.5-1.0 IHMEDTA) in comparison to several other human interferons. These results provide and ligated to the J689 fragment from the Hu-IFN-aJl gene (1, 10, some insight into structure-activity relationships for stimulating natural 11) under the following conditions: 100 ng of M13mpl8 Rf DNA killer cells and confirm our previous conclusions that antiviral activity vector fragment (EcoRl/Hincl\), 10-40 ng of fragment J689, and 0.9 cannot be used to predict other activities for an individual IFN-a species.
  • PHS 398/2590 (Rev. 06/09), Biographical Sketch Format Page

    PHS 398/2590 (Rev. 06/09), Biographical Sketch Format Page

    Program Director/Principal Investigator (Last, First, Middle): BIOGRAPHICAL SKETCH Provide the following information for the Senior/key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME POSITION TITLE Emine Ercikan Abali Associate Professor of Biochemistry, eRA COMMONS USER NAME (credential, e.g., agency login) Pharmacology and Medicine ABALIEM EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.) INSTITUTION AND LOCATION DEGREE MM/YY FIELD OF STUDY (if applicable) University of Southwestern Louisiana, Lafayette, LA B.Sc. 1982-1986 Chemistry University of Southwestern Louisiana, Lafayette, LA M.S. 1988-1988 Chemistry The Ohio State University, Columbus, OH Ph.D. student 1989-1990 Chemistry Cornell University Graduate School of Medical Ph.D. 1990-1996 Pharmacology Sciences and Memorial Sloan Kettering Cancer Center, New York, NY Memorial Sloan Kettering Cancer Center, NY, NY Postdoc 1996-1998 Molecular Therapeutics Columbia University, NY, NY Postdoc 1998-1999 Biological Sciences (10months) A. Personal Background The overall aim of this project is to use dihydrofolate reductase (DHFR) as a prototype for other NAD(P) binding dehydrogenases to identify novel NAD(P) analogues that specifically target the NADPH binding site of DHFR as potent inhibitors of cancer cells. Specifically, we plan to investigate metabolism of NADPS in cell lines and in xenograft animal and to perform in silico screening of the NADPH binding site to identify potential new inhibitors targeted to DHFR. Lastly, we will determine further characterize the mechanism of action of NADPS in accelerating the degradation of DHFR in order to address development of drug-resistance to this new class of inhibitors.
  • Extensions of Remarks E1059 HON. NANCY L. JOHNSON HON. FRANK

    Extensions of Remarks E1059 HON. NANCY L. JOHNSON HON. FRANK

    June 14, 2002 CONGRESSIONAL RECORD — Extensions of Remarks E1059 HONORING LOUISE BELKIN, FRANK and introduced the ‘‘Invention Convention’’ the now used in the clinic and stimulated the cre- JOSLYN, AND TERRY WERDEN West District School’s Grade 5. She also has ation and development of today’s extensive FOR THEIR OUTSTANDING SERV- given her time as an active member of the biotechnology industry. Dr. Pestka’s achieve- ICE AND DEDICATION TO TEACH- Farmington Education Association, and as a ments are the basis of several U.S. and for- ING AT THE WEST DISTRICT member of curriculum teams for writing, eign patents and interferon is now a major SCHOOL IN FARMINGTON, CON- science and social studies. She currently has product of several U.S. and foreign compa- NECTICUT three students whose parents she also taught nies. The market for interferon is expected to in the Farmington School system. Mrs. exceed $7 billion by 2003. HON. NANCY L. JOHNSON Werden is a dedicated public servant and her In addition to interferon’s commercial im- OF CONNECTICUT influence has been strongly felt throughout pact, there was no general antiviral therapy IN THE HOUSE OF REPRESENTATIVES West District School and the families it serves. available before Dr. Pestka began his work on Her presence within our walls will be greatly interferon; today, interferon is the first and only Thursday, June 13, 2002 missed, as she moves on to teach at Farming- general antiviral therapy. Interferon is used to Mrs. JOHNSON of Connecticut. Mr. Speak- ton’s new 5–6 school. treat hepatitis B and C, diseases that afflict er, I rise today to acknowledge the achieve- These three educators have served on the 300 million people worldwide.
  • Suppression of Spontaneous Genome Rearrangements in Yeast DNA Helicase Mutants

    Suppression of Spontaneous Genome Rearrangements in Yeast DNA Helicase Mutants

    Suppression of spontaneous genome rearrangements in yeast DNA helicase mutants Kristina H. Schmidt*†‡ and Richard D. Kolodner*§¶ *Ludwig Institute for Cancer Research and §Departments of Medicine and Cellular and Molecular Medicine and Cancer Center, University of California at San Diego, La Jolla, CA 92093; and †Division of Cell Biology, Microbiology, and Molecular Biology, Department of Biology, University of South Florida, Tampa, FL 33620 Contributed by Richard D. Kolodner, October 2, 2006 (sent for review June 16, 2006) Saccharomyces cerevisiae mutants lacking two of the three DNA the hyperrecombination and DNA-damage sensitive phenotypes of helicases Sgs1, Srs2, and Rrm3 exhibit slow growth that is sup- srs2 mutants are suppressed by HR defects (31). The physical pressed by disrupting homologous recombination. Cells lacking interaction between Srs2 and Pol32, a structural subunit of DNA Sgs1 and Rrm3 accumulate gross-chromosomal rearrangements polymerase delta, suggests that Srs2 may act during DNA replica- (GCRs) that are suppressed by the DNA damage checkpoint and by tion (32). Srs2 also is required for proper activation of Rad53 in homologous recombination-defective mutations. In contrast, rrm3, response to DNA-damaging agents (7, 33), and Srs2 itself is srs2, and srs2 rrm3 mutants have wild-type GCR rates. GCR types in phosphorylated after cells are exposed to methyl-methanesulfon- helicase double mutants include telomere additions, transloca- ate, hydroxyurea, or UV light; however, the significance of this tions, and broken DNAs healed by a complex process of hairpin- phosphorylation is unknown (33). mediated inversion. Spontaneous activation of the Rad53 check- Unlike Sgs1 and Srs2, the Rrm3 helicase has 5Ј-to-3Ј polarity and point kinase in the rrm3 mutant depends on the Mec3͞Rad24 DNA shares homology throughout its helicase domain with the S.
  • Contributions of Cloned Type I Interferon Receptor Subunits to Differential Ligand Binding

    Contributions of Cloned Type I Interferon Receptor Subunits to Differential Ligand Binding

    FEBS 18274 FEBS Letters 404 (1997) 197-202 Contributions of cloned type I interferon receptor subunits to differential ligand binding Elizabeth Cali Cutronea, Jerome A. Langera'b'* aDepartment of Molecular Genetics and Microbiology, UMDNJ-Robert Wood Johnson Medical School, Piscataway, NJ 08854, USA h Cancer Institute of New Jersey, UMDNJ-Robert Wood Johnson Medical School, 675 Hoes Lane, Piscataway, NJ 08854, USA Received 20 January 1997 IFNAR-1) [5] has weak intrinsic affinity for at least two Abstract The human type I interferons, including at least 12 IFN-as, IFN-P and IFN-co, bind to a receptor (IFNAR) IFNs, IFN-a2 and -a8 [6,7]. Its expression confers on rodent composed of at least two transmembrane subunits, IFNAR-1 cells limited responsiveness and binding of human type I IFNs and IFNAR-2. The contributions of the receptor subunits to [5], and enhances the ability of monkey-derived COS cells to ligand binding were investigated by measuring the binding bind human IFNs [8]. In contrast to HuIFNAR-1, the bovine properties of IFNAR-1 or IFNAR-2 alone, or when co- homologue (BoIFNAR-1) fortuitously binds human IFN-as expressed. The affinity of IFNAR-2 for IFN-ct2 was increased with high affinity [6,9,10]. The ability of antibodies against by the co-expression of IFNAR-1, which itself binds ligand very HuIFNAR-1 to block the binding of various type I interfer- weakly. Most type I IFNs inhibited the binding of IFN-ot2 to ons to human cells [11,12] suggests that IFNAR-1 is involved IFNAR-2 alone with IC50 values of 2-20 nM.
  • Sydney Udenfriend 1918– 1999

    Sydney Udenfriend 1918– 1999

    NATIONAL ACADEMY OF SCIENCES SYDNEY UDENFRIEND 1918– 1999 A Biographical Memoir by HERBERT WEISSBACH AND BERNHARD WITKOP Any opinions expressed in this memoir are those of the authors and do not necessarily reflect the views of the National Academy of Sciences. Biographical Memoirs, VOLUME 83 PUBLISHED 2003 BY THE NATIONAL ACADEMIES PRESS WASHINGTON, D.C. Taken from the Annual Report of the Roche Institute of Molecular Biology SIDNEY UDENFRIEND April 5, 1918–December 29, 1999 BY HERBERT WEISSBACH AND BERNHARD WITKOP IDNEY UDENFRIEND’S PARENTS emigrated to the United S States from an Austro-Polish region in central Eu- rope in 1913. They had three children; the oldest was Sidney, who was born in Brooklyn, New York, on April 5, 1918. After attending public schools in Brooklyn Udenfriend en- tered the City College of New York (CCNY) in 1935. At that time CCNY was the dream for so many of the immigrant parents who wanted their children to obtain a college edu- cation. Supported by public funds, with no tuition, CCNY provided that opportunity for those students who could pass the rigid requirements for entrance. The Chemistry De- partment was well recognized in the field of physiological chemistry (or biochemistry) thanks in large part to Ben- jamin Harrow, who wrote a widely used textbook. Harrow had a great influence on Udenfriend, and after graduation in 1939 Udenfriend was set on a career in bio- chemistry and determined to go to graduate school. In 1940 he was accepted at New York University Graduate School in the Department of Biology working with Kenneth Blanchard.
  • 2008 MD/Phd Program

    2008 MD/Phd Program

    Robert Wood Johnson Medical School MD/PhD Program Symposium Thursday, July 31, 2008 Department of Molecular Biology Carl Icahn Laboratory Princeton University Princeton, New Jersey Program Continental Breakfast 8:30 to 9:00 a.m. Introductory Remarks 9:00 to 9:30 a.m. Terri Goss Kinzy, PhD Assistant Dean for Medical Scientist Training Director, UMDNJ-RWJMS/Rutgers/Princeton MD/PhD Program Professor, Department of Molecular Genetics, Microbiology, and Immunology, UMDNJ-RWJMS James Broach, PhD Associate Director, Lewis-Sigler Institute for Integrative Genomics, Princeton University Professor and Associate Chair, Department of Molecular Biology, Princeton University Student Presentations (Session 1) 9:30 to 10:30 a.m. Break 10:30 to 10:45 a.m. Student Presentations (Session 2) 10:45 to 11:45 a.m. Break 11:45 to 12:00 p.m. Dean’s Welcome Remarks 12:00 to 12:15 p.m. Peter Amenta, MD, PhD Interim Dean, UMDNJ-RWJMS Professor and Chair, Department of Pathology and Laboratory Medicine, UMDNJ-RWJMS Luncheon 12:15 to 2:00 p.m. Student Presentations (Session 3) 2:00 to 3:00 p.m. Break 3:00 to 3:15 p.m. Keynote Address 3:15 to 4:15 p.m. Leon Rosenberg, MD Professor, Department of Molecular Biology, Princeton University and Woodrow Wilson School of Public and International Affairs “Questions a Physician-Scientist Asks About Life” Concluding Remarks 4:15 to 4:30 p.m. Elizabeth Gavis, MD, PhD Princeton Liason, UMDNJ-RWJMS/Rutgers/Princeton MD/PhD Program Professor, Department of Molecular Biology, Princeton University Reception 4:30 p.m. Acknowledgments: The MD/PhD Symposium was made possible by the support of Dr.
  • Mechanisms of Recombination: 50 Th Anniversary Meeting of the Holliday Model

    Mechanisms of Recombination: 50 Th Anniversary Meeting of the Holliday Model

    Mechanisms of Recombination: 50 th Anniversary Meeting of the Holliday Model May 19-23, 2014 Alicante, Spain Monday, May 19 Afternoon Arrival 17:00 Registration 18:30 Welcome drinks 19:30 Keynote lectures: Scott Keeney (Memorial Sloan Kettering Cancer Center, US) Mechanism and regulation of meiotic recombination initiation David Sherratt (University of Oxford, UK) Recombination in live bacteria Dinner Tuesday, May 20 Breakfast Session 1 Chairperson : Lorraine Symington 09:00 – 09:25 Roland Kanaar (Erasmus MC, The Netherlands) Molecular mechanism of homologous recombination 09:25 – 09:50 Patrick Sung (Yale University, US) Regulation of homologous recombination by DNA helicases 09:50 – 10:15 Steve Kowalczykowski (University of California, Davis, US) Seeing recombination: one molecule and step at a time 10:15 – 10:30 Xiaodong Zhang (Imperial College London, UK) Structural characterisations of BRCA2 provide mechanistic insights into Rad51 binding and filament formation during homologous recombination Break 11:00 – 11:25 Akira Shinohara (Osaka University, Japan) Assembly and disassembly of Rad51 complex by Rad51 mediators and DNA helicases 11:25 – 11:50 Hiroshi Iwasaki (Tokyo Institute of Technology, Japan) The activation of Rad51-dirven DNA strand exchange reaction by the Swi5-Sfr1 complex 11:50 – 12:15 Wolf-Dietrich Heyer (University of California, Davis, US) Mechanism and regulation of recombinational DNA repair 12:15 – 12:40 Doug Bishop (University of Chicago, US) Recombinosome architecture and homolog bias in meiotic recombination 12:40